Cytek expands Cloud Analysis and Cytek Biosciences stock costs EUR 5.18
Cytek Biosciences has expanded its Cytek Cloud platform by introducing a new Cloud Analysis tool and a Premium subscription tier. The platform, which has over 28,000 users, allows researchers to import experimental data and perform analysis in the cloud, aiming to integrate a subscription feature into existing research workflows. Despite a 6% increase in Q2 2026 revenue to $48.10 million, the company reported an increased net loss of $12.20 million, although it raised the lower end of its full-year revenue guidance.
Cytek Biosciences Adopts Amended Bylaws Tightening Stockholder Nomination Rules
Cytek Biosciences, Inc. has amended its bylaws to tighten stockholder nomination and proposal rules, effective September 23, 2026. These changes are procedural governance updates aimed at modernizing the company's rules, rather than reflecting business or financial developments. The amendments include requirements for stockholders to provide additional information, certify share ownership, and comply with universal proxy rules, expanding the chairperson's authority to disregard non-compliant nominations.
Form 8K Cytek Biosciences Inc For: 29 September By Investing.com
This article announces that Cytek Biosciences Inc. has filed a Form 8K for September 29. The filing is brief, providing only the date and the company concerned, and includes its stock symbol CTKB with a recent performance percentage. The article is from Investing.com and was published on September 29, 2026.
Form 8K Cytek Biosciences Inc For: 29 September By Investing.com
This article reports on the filing of a Form 8K by Cytek Biosciences Inc. on September 29. The brief notice from Investing.com indicates this as a significant corporate event, providing the company's stock symbol CTKB and showing a slight positive change in its stock price. The article provides no further details regarding the content of the Form 8K.
Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability
Brown Capital Management's Small Company Fund divested its holdings in Cytek Biosciences (CTKB) in Q2 2026 due to poor stock performance, slowing revenue growth, and declining profitability. The life sciences technology company, based in Fremont, California, faced pressure from a softer spending environment, budget constraints in life sciences tools, and increased competition. The fund noted that CTKB's growth and profitability profile had deteriorated since their initial investment, leading them to remove it from their portfolio in favor of AI stocks with greater upside potential.
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Cytek Biosciences has expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, creating the industry's first end-to-end platform for flow cytometry. This tool integrates the entire workflow from panel design to data analysis, allowing researchers to seamlessly transition between experiment design, data acquisition, and analysis. The company also introduced a new Cytek Cloud Premium license, offering cloud-based data analysis and online storage.
Cytek introduces new end-to-end flow cytometry workflow
Cytek Biosciences has expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, integrating the entire flow cytometry workflow from panel design to data analysis into a single system. This innovation allows researchers to seamlessly move from experiment planning to data analysis, preserving experimental data and enabling direct import from SpectroFlo® desktop software. The platform, which supports Cytek Northern Lights™, Cytek Aurora®, Cytek Aurora® Evo, and Cytek Aurora® CS systems, also features an AI-powered SpectroPanel™ tool for automated fluorochrome assignment and offers various subscription tiers to meet different research needs.
Cytek Biosciences launches cloud-based analysis tool
Cytek Biosciences (NASDAQ:CTKB) has expanded its Cytek Cloud digital ecosystem by introducing a new Cloud Analysis tool. This new feature integrates the entire flow cytometry workflow, from panel design to data analysis, allowing researchers to access their work from various devices. The company is offering three subscription tiers for Cytek Cloud, with the Premium tier including the Cloud Analysis tool and online data storage, currently for U.S. customers.
Cytek Biosciences launches cloud-based analysis tool By Investing.com
Cytek Biosciences, Inc. (NASDAQ:CTKB) has expanded its Cytek Cloud digital ecosystem by launching a new Cloud Analysis tool. This addition integrates the flow cytometry workflow from panel design to data analysis, allowing researchers to import data and access their work from various devices. The company is offering three subscription tiers for Cytek Cloud, with the Cloud Analysis tool currently available to U.S. customers under the Premium tier.
Cytek Biosciences Expands Cytek Cloud with New Cloud Analysis Tool for End-to-End Flow Cytometry Workflow
Cytek Biosciences has expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, creating the industry's first end-to-end platform for flow cytometry workflows. This integration allows researchers to seamlessly move from panel design to data analysis, preserving experimental data and increasing efficiency. The platform now offers new subscription tiers, including Cytek Cloud Premium, which provides enhanced capabilities like cloud-based data analysis and online storage for U.S. customers.
A new tool lets researchers analyze cell data online without rebuilding their work
Cytek Biosciences (CTKB) has enhanced its Cytek Cloud platform with a new Cloud Analysis tool, allowing researchers to analyze experimental data online and access it from various devices without rebuilding their work. This addition integrates the entire flow cytometry workflow and introduces a Premium subscription tier that includes cloud-based analysis and online storage, currently available only in the U.S. The platform aims to provide a seamless research experience from panel design to data analysis, building on its existing suite of tools and growing user base.
Cytek Biosciences stock gains 2.25 percent near its yearly range
Cytek Biosciences (CTKB) stock gained 2.25 percent to USD 4.72 on September 21, 2026, reaching a market capitalization of USD 600.51 million. The stock's performance reflects market reaction, though no specific company-related reason for the move was identified in the available data. The article highlights the company's trading statistics and market valuation as key data points for investors.
Cytek Biosciences stock edges higher after recent earnings and analyst interest
Cytek Biosciences stock is trading in a tight range, with investors evaluating recent quarterly results and the company's growth outlook. While the stock is below its 52-week high, analysts see upside potential due to its differentiated technology in flow cytometry, balanced against execution risks and competitive pressures. The company's latest financials showed double-digit revenue growth and improving operating leverage, though net income remains modest due to continued investments.
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
The options market is showing high implied volatility for Cytek Biosciences (CTKB) stock, particularly for the October 16, 2026 $02.50 Put, suggesting investors anticipate a significant price movement. Despite this, analysts currently rate Cytek Biosciences as a Zacks Rank #3 (Hold), with recent estimate revisions indicating a move towards a break-even point for the current quarter. This discrepancy could signal a potential trading opportunity for options traders to sell premium.
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
The options market is showing high implied volatility for Cytek Biosciences (CTKB), particularly for the October 16, 2026 $2.50 Put, suggesting investors anticipate a significant price movement. Despite this, analysts currently rate Cytek Biosciences as a Zacks Rank #3 (Hold), with recent estimate revisions indicating a less optimistic fundamental outlook. This high implied volatility, coupled with analysts' cautious sentiment, might present a potential trading opportunity for those looking to sell premium.
Sysmex Europe SE and Cytek Biosciences Announce Strategic Collaboration to Expand Clinical Flow Cytometry Access Across Europe
Sysmex Europe SE and Cytek Biosciences have formed a strategic collaboration to enhance clinical flow cytometry workflows and expand access to diagnostic solutions across more than a dozen European countries. This partnership integrates Sysmex's routine testing portfolio with Cytek's Northern Lights™-CLC spectral flow cytometer, providing laboratories with comprehensive, efficient, and standardized solutions for complex diagnostic testing, such as leukemia and lymphoma. The collaboration aims to streamline processes from sample preparation to advanced multi-color analysis, meeting the growing demand for rapid and standardized diagnostics in clinical settings.
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
Sysmex Europe and Cytek Biosciences have announced a strategic collaboration across over a dozen European countries to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. This partnership will provide clinical laboratories with an integrated, end-to-end solution, combining Sysmex's automation and routine flow cytometry expertise with Cytek's advanced spectral flow cytometry technology. The goal is to improve workflow efficiency, standardization, and advanced clinical capabilities for laboratories managing complex diagnostic requirements.
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
Sysmex Europe and Cytek Biosciences have announced a strategic collaboration to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions across more than a dozen European countries. This partnership will integrate Sysmex's established clinical flow cytometry portfolio with Cytek's Northern Lights™-CLC spectral flow cytometer, offering laboratories a comprehensive, end-to-end solution from sample preparation to advanced multi-color analysis. The collaboration aims to improve workflow efficiency, standardization, and advanced clinical capabilities for laboratories facing growing demands for faster and more complex diagnostic testing.
European labs can combine routine testing with advanced leukemia and lymphoma analysis
Cytek Biosciences and Sysmex Europe are collaborating to offer integrated clinical flow cytometry solutions in over a dozen European countries. This partnership combines Sysmex's automated sample preparation and routine flow testing with Cytek's advanced spectral flow cytometry to streamline workflows for complex diagnostic applications like leukemia and lymphoma analysis. The goal is to provide laboratories with an end-to-end solution that enhances efficiency, standardization, and diagnostic capabilities.
More than 4,200 peer-reviewed papers cite Cytek’s systems. It will showcase them at two fall meetings.
Cytek Biosciences (CTKB) will showcase its spectral flow cytometry solutions and Full Spectrum Profiling™ (FSP®) technology at the ESCCA 2026 Conference and ICCS 2026 meeting this fall. These events focus on clinical cytometry applications, and Cytek's technology is cited in over 4,200 peer-reviewed publications. The company aims to advance the adoption of spectral flow cytometry in clinical research by enabling deeper cellular insights and streamlined workflows.
Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
Cytek Biosciences will showcase its advanced spectral flow cytometry solutions at the ESCCA 2026 Conference and ICCS 2026 Annual Meeting. The company's Full Spectrum Profiling (FSP) technology allows for deeper cellular insights, streamlined workflows, and expanded analytical capabilities in clinical research. Cytek aims to advance the adoption of spectral flow cytometry across various clinical applications, including MRD research.
Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences (Nasdaq: CTKB) announced its participation in three upcoming investor conferences in September 2026. CFO William McCombe will attend the Wells Fargo 21st Annual Healthcare Conference, while CEO Wenbin Jiang and CFO William McCombe will present at the Morgan Stanley 24th Annual Global Healthcare Conference and Deutsche Bank's 2026 Healthcare Summit. A webcast of the Morgan Stanley event will be available on the company's investor relations website.
Cytek Owes Beckman Coulter $56 Million at Patent Jury Trial (2)
A federal jury in Delaware has ordered Cytek Biosciences Inc. to pay Beckman Coulter Inc. $56.1 million for infringing on a patent related to tools for analyzing individual cells. The verdict includes $20 million in lost profits and $36.11 million in royalties for Cytek's infringing sales of flow cytometers. The patent in question is Beckman Coulter’s US Patent No. 10,330,582, covering a flow cytometer design, which Cytek's Aurora flow cytometers were found to infringe.
Cytek Biosciences Shares Drop After Jury Says It Owes $56 Million in Damages
Cytek Biosciences' shares dropped by 7.2% after a jury ruled that the company owes $56 million in damages for patent infringement to Beckman Coulter. Although Cytek won on three of four claims, the jury found infringement under the doctrine of equivalents on the remaining claim, awarding $20 million in lost profit and $36.1 million in royalties. Cytek plans to challenge the jury's decision.
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
A jury in the United States District Court for the District of Delaware found in Cytek Biosciences' favor on three of four asserted patent claims in an infringement case brought by Beckman Coulter, Inc. While the jury found no literal infringement on any claim, it did find infringement under the doctrine of equivalents for one claim, awarding $56 million in damages. Cytek intends to challenge this remaining finding and damages award through post-verdict motions and potentially an appeal, asserting that the verdict does not necessitate changes to its current products or operations.
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
A jury in the U.S. District Court for the District of Delaware largely sided with Cytek Biosciences in a patent infringement case brought by Beckman Coulter, finding in Cytek's favor on three of four asserted claims. While the jury found non-infringement and invalidity for three claims, one claim was found infringed under the doctrine of equivalents, with damages awarded at $20 million in lost profits and $36 million in royalties. Cytek Biosciences intends to challenge this remaining finding and the damages award through post-verdict motions and potentially an appeal, asserting no impact on its current product offerings or operations.
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
A jury found in Cytek Biosciences' favor on three of four asserted patent claims in an infringement case brought by Beckman Coulter, Inc., determining non-infringement and invalidity for those claims. However, the jury found infringement on one claim under the doctrine of equivalents and awarded $20 million in lost profits and $36 million in royalties. Cytek plans to challenge this remaining finding and damages award, asserting that its product offerings and operations will not be affected.
Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent
A Delaware federal jury has awarded Beckman Coulter approximately $56 million in damages after finding that Cytek Biosciences infringed one of its patents related to cell-sorting technology. The patent covers a technology used for quickly analyzing single cells. The verdict was reached on Friday, August 21, 2026.
Cytek owes Beckman Coulter $56 mln in cell-analysis patent case, US jury says
A Delaware federal jury has ruled that Cytek Biosciences must pay Beckman Coulter $56 million for infringing on a patent related to cell-analysis technology. The jury found Cytek's Aurora flow cytometers violated Beckman's patent rights used in its CytoFLEX platform, awarding $36 million in royalties and $20 million in lost profits. Cytek plans to appeal the decision, despite the jury finding in its favor on two other patents.
Cytek Biosciences wins on three of four patent claims
Cytek Biosciences secured a victory in a patent infringement case, with a jury finding in its favor on three out of four asserted patent claims brought by Beckman Coulter. While found liable for infringement under the doctrine of equivalents on the remaining claim, Cytek intends to challenge the $56 million damages award and confirmed its product offerings and operations remain unchanged. The company, a cell analysis solutions provider, expressed disagreement with the single adverse finding and plans to pursue all available post-trial remedies.
Cytek products remain available worldwide after jury awards $36M in royalties
A Delaware jury awarded Beckman Coulter $56 million in damages ($20 million in lost profits and $36 million in royalties) in a patent infringement case against Cytek Biosciences, though Cytek won on three of four asserted claims. Cytek plans to challenge the remaining infringement finding and damages, asserting that its products remain available globally and require no changes. The company highlighted its intention to pursue post-verdict motions and potentially appeal the decision.
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
A jury in the United States District Court for the District of Delaware found in Cytek Biosciences' favor on three of four patent infringement claims brought by Beckman Coulter, Inc. While the jury found noninfringement and invalidity for three claims, it found infringement under the doctrine of equivalents for one claim, awarding $56 million in damages. Cytek intends to challenge this remaining finding and damages award through post-verdict motions and potentially an appeal, asserting no changes to its current product offerings or operations are required.
Cytek Biosciences (CTKB) CTO gets 33,270 shares, surrenders some for taxes
Cytek Biosciences (CTKB) Chief Technology Officer Yan Ming acquired 33,270 shares of common stock through the vesting of Restricted Stock Units (RSUs) on August 18, 2026. To cover tax obligations related to these vestings, 8,088 shares were withheld by Cytek at a price of $4.67 per share. The RSU awards vest over four-year schedules with specific fractions vesting on set dates throughout the year.
Cytek Biosciences CFO William D. McCombe Executes RSU Vesting and Tax Withholding Transactions
Cytek Biosciences CFO William D. McCombe has executed the vesting of three restricted stock unit (RSU) awards and associated tax withholding transactions on August 18, 2026. This resulted in the acquisition of 35,420 shares and the withholding of 11,904 shares for tax liabilities at $4.67 per share. Following these transactions, McCombe directly owns 134,693 shares of Cytek Biosciences common stock and retains 409,153 outstanding RSUs.
Cytek Biosciences Director Glenn P. Muir Converts 3,086 RSUs to Common Stock on August 18, 2026
Cytek Biosciences Director Glenn P. Muir converted 3,086 restricted stock units (RSUs) into common shares on August 18, 2026, as detailed in a recent Form 4 filing. This transaction, coded M, means he now directly holds these shares, with 52,469 RSUs remaining under a multi-year vesting schedule. The conversion took place at no cost to Muir, and the vesting schedule extends through 2027.
Cytek Biosciences (NASDAQ: CTKB) director gains 3,086 no-cost shares
Cytek Biosciences director Glenn P. Muir converted 3,086 Restricted Stock Units (RSUs) into common stock on August 18, 2026, at a price of $0.00 per share. Following this transaction, Muir directly holds 3,086 shares of common stock and an RSU balance of 52,469 units related to this award. The RSUs vest over three years in multiple tranches, with specific vesting dates outlined through August 2027.
Cytek Biosciences (CTKB) director now holds 28,499 shares
Cytek Biosciences director Richard Chin converted 6,107 Restricted Stock Units (RSUs) into common stock on August 18, 2026, increasing his direct common stock holdings to 28,499 shares. He still holds 44,790 RSUs, which vest in tranches over three years. This transaction is part of a scheduled RSU award vesting, as detailed in a Form 4 SEC filing.
Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer
Cytek Biosciences (CTKB) has granted new equity awards to its Chief Legal Officer and Secretary, Ilan Feuchtwang. These awards include 241,416 Restricted Stock Units (RSUs) and an option to purchase 127,118 shares of common stock at an exercise price of $4.66 per share. Both the RSUs and options will vest over a four-year period, contingent upon Feuchtwang's continuous service to the company.
Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments
Cytek Biosciences is seeing its recurring revenue, from service and reagent sales, grow as it expands its global installed base of instruments and introduces new cell-analysis platforms. Recurring revenue now accounts for 35% of total sales on a trailing 12-month basis, up from 32% a year prior, while the installed base neared 4,000 instruments. The company also launched new products like Borealis and expanded Aurora Evo configurations, contributing to a 6% increase in Q2 revenue and a raised full-year revenue outlook.
Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations
This article provides analyst insights, price targets, and recommendations for Cytek Biosciences, Inc. (8EQ.MU). It lists several recent analyst actions including upgrades, downgrades, and maintained ratings from firms like Piper Sandler, Goldman Sachs, Stephens & Co., and Morgan Stanley, along with the corresponding dates. The stock's current trading price is also displayed.
Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A
Millennium-affiliated entities and Israel A. Englander have filed an amended Schedule 13G/A, disclosing significant ownership stakes in Cytek Biosciences, Inc. Integrated Core Strategies (US) LLC reported a 5.5% beneficial ownership, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported 7.2% beneficial ownership, all with shared voting and dispositive power. The filing emphasizes that this structure does not, by itself, constitute an admission of beneficial ownership by the reporting persons.
Cytek Biosciences, Inc. 2Q 2026: Revenue $48.14M, EPS ($0.09) — 10-Q Summary
Cytek Biosciences, Inc. reported its second-quarter 2026 results, showing a 5.6% year-over-year revenue increase to $48.14 million, alongside a net loss of $12.16 million and diluted EPS of ($0.09). Revenue growth was fueled by product and service gains, with improved gross margin attributed to tariff refunds and lower service material costs. The company also expanded its direct and distributor sales channels and invested in R&D and global hiring.
Cytek Biosciences, Inc. (CTKB) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Cytek Biosciences, Inc. (CTKB), including its current stock price, recent news, historical data, and financial analysis. The company specializes in cell analysis solutions for biomedical research and clinical applications, offering various instruments and reagents. The article also details CTKB's earnings trends, analyst insights, valuation measures, and allows for comparison with similar medical device companies.
Cytek Biosciences Reports Second Quarter 2026 Financial Results
Cytek Biosciences reported its second-quarter 2026 financial results, with total revenue reaching $48.1 million, a 6% increase year-over-year. The company also announced the launch of new instruments, the Cytek Borealis™ and updated Cytek Aurora™ Evo configurations, and updated its full-year 2026 revenue guidance to $207 million to $212 million. Despite increased operating expenses and a net loss, the company highlighted strong instrument growth and recurring revenue expansion.
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
Cytek Biosciences (CTKB) reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong growth in the US and China, particularly from high-end instrument sales and services. Despite this, the company saw a widened GAAP net loss of $12.2 million and a negative Adjusted EBITDA, primarily due to increased operating expenses and softness in the EMEA region. Cytek raised its full-year revenue guidance to $207 million-$212 million and maintains a strong cash balance, with expectations for continued growth driven by new product launches like the Borealis and strategic reorganization.
Cytek Biosciences, Inc. - Common Stock (CTKB) Stock Price, News, Quote & History
This page provides detailed stock information for Cytek Biosciences, Inc. (CTKB), including its current price, trading data, and company overview. It also features a collection of recent news and press releases highlighting the company's financial results, new product launches, expansion efforts, and industry recognitions.
Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong growth in the U.S. and China, despite weakness in Europe and parts of Asia-Pacific. The company expanded its installed base to 3,933 instruments and saw recurring revenue grow by 8%. Despite a widening GAAP net loss, Cytek raised its full-year 2026 revenue outlook.
Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million
Cytek Biosciences reported its Q2 2026 financial results, showing a 6% year-over-year increase in revenue to $48.1 million. Despite the revenue growth, the company's GAAP net loss widened to $12.2 million, and its GAAP operating loss increased to $11.4 million. The gross margin improved to 59%, and the company raised its full-year 2026 revenue guidance to between $207 million and $212 million.
Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss
Cytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1 million, a 5.6% increase year-over-year, and gross profit rose by 18.7% to $28.3 million. Despite revenue growth, the company posted a net loss of $12.2 million, or $(0.09) diluted EPS, missing analyst expectations of $(0.0867) EPS and $49.6 million in revenue. The article also details hedge fund activity, government contracts, and analyst price targets for CTKB.
Cytek Q2 2026 Earnings: Revenue Rose 6% as Losses Widened
Cytek (Nasdaq: CTKB) reported a 6% increase in Q2 2026 revenue to $48.1 million, driven by instrument growth in the U.S. and China and higher service revenue. However, the company's net losses widened significantly due to a faster increase in operating expenses and weaker non-operating results. A one-time tariff refund boosted reported gross margin, but excluding this, the underlying margin was flat, while adjusted EBITDA turned negative, highlighting ongoing profitability challenges.
